RNS Number : 9790C
MaxCyte, Inc.
22 October 2020
Disclosure of Remuneration for Non-Audit Services
Gaithersburg, Maryland - 22 October 2020:
MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an update to its previous disclosure of remuneration for audit-related services.
The Company previously disclosed on 14 October 2020 that the remuneration of the Company's auditors, Cohn Rezhnick LLC, for services relating to the 2019 financial year, amounted to approximately $137,000.
In order to further assist investors in considering the resolutions proposed ahead of the Company AGM, MaxCyte advises that these fees consisted of $119,000 for audit services and $18,000 for tax services, with no further costs incurred for any other services.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit
www.maxcyte.com
.
###
Contacts:
|
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
|
+1 301-944-1660
|
|
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith
|
+44 (0)20 7260 1000
|
|
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
--------------------------------------------------------------
|
+44 (0)203 709 5700
maxcyte@consilium-com
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
MSCKKBBBOBDDDKB
|
